The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
India’s institutions now need to upgrade TTOs as strategic innovation units rather than administrative support cells
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
